Healthcare stocks were mostly higher, with the NYSE Healthcare
Sector Index rising 0.5% and shares of healthcare companies in the
S&P 500 up about 0.5% as a group.
In company news, shares of Sangamo BioSciences (
) rallied to a 13-year high Thursday after the company late
Wednesday reported positive clinical trial results for an
experimental treatment for HIV.
SGMO has been working on gene-editing technology that can be
used to insert a corrective gene into patients, replacing a
defective one. According to a study published Wednesday in the New
England Journal of Medicine, the company was able to take T-cells
from HIV patients and modify them by knocking out a gene called
CCR5, providing the patient with a natural resistance to HIV
infection after the cells were reinserted.
Some of the patients treated with the SB-728-T therapy had lower
virus levels after 12 weeks of treatment, according to SGMO.
SGMO shares were ahead just nearly 21% at $23.69 apiece, after
earlier climbing to their best level since January 2001 at $23.95
In other sector news,
(+) TKMR, (+3.9%) Receives Fast Track designation from FDA for
its anti-Ebola viral therapeutic.
(-) BIOL, (-10.2%) Reports Q4 GAAP loss of $0.06 per share,
trailing Capital IQ consensus by $0.02. Revenue falls 20.1% year
over year to $15.2 mln, missing Street view by $600,000.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.